IT   EN

Ultimi tweet

Advanced cervical cancer: bevacizumab plus chemotherapy improved survival compared to chemotherapy alone #asco13

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the results of a large, independent study (GOG240) sponsored by the US National Cancer Institute (NCI) and conducted by the Gynecologic Oncology Group (GOG), which showed that the addition of bevacizumab to chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) extended the lives of women with advanced cervical cancer, compared to chemotherapy alone.

The study met its primary endpoint of improving overall survival with a statistically significant 29% reduction in the risk of death for women who received bevacizumab plus chemotherapy compared to those who received chemotherapy alone (HR=0.71, p=0.0035).

Women who received bevacizumab plus chemotherapy lived a median of 3.7 months longer compared to those who received chemotherapy alone; the median overall survival (OS) was 17 months with bevacizumab plus chemotherapy compared to 13.3 for chemotherapy alone. No new safety signals related to bevacizumab were observed and overall safety was consistent with that seen in previous pivotal studies of bevacizumab across different tumour types.


“Worldwide, cervical cancer is the third most common cancer in women, and those who have an advanced form of this cancer need new medicines”, said Hal Barron, M.D., chief medical officer and head, Global Product Development. “We’d like to thank the GOG for their leadership and the NCI for their support of the study. We plan to discuss these encouraging data with regulatory authorities.”


It is estimated that there are more than half a million cases of cervical cancer worldwide each year,1 with approximately 85% of those in developing countries.1 Besides effective treatment, it is also critical that more women have access to vaccination against human papilloma virus (HPV; the cause of the vast majority of cervical cancers) and to screening for precancerous lesions. These approaches can prevent women from developing advanced clinical disease.

The GOG240 data will be presented today in the plenary session of the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) by Dr. Krishnansu Sujata Tewari, University of California, Irvine Medical Center (Abstract 3, Sunday, June 2, 1:00 PM CDT).


GOG240 study results

  • bevacizumab in combination with chemotherapy reduced the risk of death by 29 % compared to chemotherapy alone (HR=0.71, p=0.0035).

  • Median overall survival was 17.0 months for women who received bevacizumab plus chemotherapy compared to 13.3 months for chemotherapy alone.

  • Women who received bevacizumab plus chemotherapy experienced a 33 % reduction in the risk of disease worsening or death (progression-free survival; PFS) compared to chemotherapy alone (median PFS: 8.2 months vs. 5.9 months; HR=0.67, p<0.002)

  • bevacizumab plus chemotherapy shrank more tumours (response rate) than chemotherapy alone (48% versus 36%, respectively, p=0.0078).

  • No new safety signals were observed and the overall safety was consistent with that seen in previous pivotal studies of bevacizumab across tumour types